Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the results of QUAZAR AML-001 (NCT01757535), a Phase III study aiming to improve the overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML) patients. Patients in first remission after intensive chemotherapy (IC) were treated with CC-486, an oral hypomethylating agent, or placebo. The CC-486 arm patients were found to have improved OS and RFS rates when compared to those in the placebo arm, regardless of the number of consolidation cycles received. These findings raise many questions, including when consolidation cycles should be replaced by maintenance therapy and how outcomes of CC-486 maintenance therapy can be improved, for example by combining it with other agents. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.